GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | MicrobiomeTrials← Back to trialsNCT06379113
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2022-07-13Est. Completion: 2028-03-30
Enrollment target: 29 participants Locations- Tenth People's Hospital of Tongji University, Shanghai, Shanghai Municipality, China
- Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China
Other microbiome trials you might be interested in
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaUterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, t…
Birmingham, United StatesEst. completion Oct 31, 2027
Recruiting
Grade 1 Endometrial Endometrioid CarcinomaEndometrial Intraepithelial NeoplasiaMetabolic Comorbidities
This single-arm study will evaluate the feasibility, safety, and preliminary efficacy of tirzepatide in combination with…
Hershey, United StatesEst. completion May 1, 2028
Endometrial NeoplasmsAtypical Endometrial HyperplasiaProgesterone Resistance
To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-…
Shanghai, ChinaEst. completion Mar 30, 2028